Antibodies News and Research

RSS

Furin cleavage site and D614G on SARS-CoV-2 spike evolved to balance infectivity, stability, cytopathicity

SARS-CoV-2 is the causative agent of COVID-19 disease, currently raging across the world. The virus has now infected more than 43.89 million individuals and claimed over 1.16 million lives. The study titled, "Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects," is released on the preprint server bioRxiv* in October 2020.

27 Oct 2020

Myeloid cells can suppress immune response, promote brain metastasis

Scientists have long believed that the brain protects itself from an aggressive immune response to keep down inflammation. However, that evolutionary control may work against it when a cancer cell attempts to spread to the brain, researchers at the University of Notre Dame have discovered.

27 Oct 2020

Research on autophagy and coronavirus, implicates ULK1

Researchers from the University of British Columbia have discovered that the betacoronavirus-encoded papain-like protease disrupts autophagy, partly by targeting ULK1. Their work is reported on the preprint server bioRxiv* in October 2020.

27 Oct 2020

Study: SARS-CoV-2 virus adopts new strategy to ensure its replication, spread

Since COVID-19 began its menacing march across Wuhan, China, in December 2019, and then across the world, the SARS-CoV-2 virus has taken a "whatever works" strategy to ensure its replication and spread.

27 Oct 2020

Lung biomarkers may predict severe COVID-19

Two University of New Mexico researchers postulate certain specific biomarkers' relevance in predicting the potential for progression to severe COVID-19 in a paper published on the preprint server bioRxiv*

27 Oct 2020

Phase 1 trial results of gorilla adenovirus vaccine for COVID-19

A recent study published on the preprint server bioRxiv* in October 2020 reports the development of a novel vaccine based on a simian adenoviral vector obtained from a group C gorilla isolate called GRAd32. This could help speed up vaccine development.

26 Oct 2020

New peptide derivatives that target the SARS-CoV-2 spike protein

In a new study published in the journal Cellular and Molecular Bioengineering, researchers report peptide derivatives, or peptidomimetics, based on the circle residues involved in the interaction of the spike protein and ACE2.

26 Oct 2020

Small molecules block SARS-CoV-2 spike-ACE2 attachment

The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.

26 Oct 2020

Population-based COVID-19 prevalence surveys in Europe and Americas show risk of bias

A team of researchers from the Federal University of Health Sciences of Porto Alegre and the Federal University of Rio Grande do Sul performed a systematic review to assess these population-based COVID-19 prevalence surveys' reliability and biases qualitatively. Their study is published on the preprint server medRxiv.

26 Oct 2020

NRP-1 receptor potentiates SARS-CoV-2 infectivity

The COVID-19 pandemic is still actively spreading in many parts of the world, causing redoubled efforts to develop antivirals and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A recent study explores the role of a second type of cell surface receptor, called neuropilin, in the virus's entry into the host cell and its subsequent replication.

26 Oct 2020

Startling high SARS-CoV-2 seroprevalence in Veracruz, Mexico

A surprising new study published on the preprint server medRxiv in October 2020 reports a very high seroprevalence of IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the city of Vera Cruz, Mexico. They are among the highest to be reported anywhere in the world.

25 Oct 2020

Neuropilin-1: A new route of SARS-CoV-2 entry

A new study published in the reputed journal Science in October 2020 reports the potential therapeutic value of the second type of host transmembrane receptor, called neuropilins, which attach to the spike protein of SARS-CoV-2 and may enhance its infectivity.

25 Oct 2020

Scientists devise new method to map HIV's sugary shield in unprecedented detail

Scientists from Scripps Research and Los Alamos National Laboratory have devised a method for mapping in unprecedented detail the thickets of slippery sugar molecules that help shield HIV from the immune system.

23 Oct 2020

Mathematical modeling study offers new insights into optimal timing of antiviral therapies against COVID-19

A new mathematical modeling study by Ashish Goyal and colleagues, informed by data collected from 25 patients hospitalized with COVID-19 in 4 different countries, offers some important new insights into the optimal timing of 4 different antiviral therapies to combat the disease.

23 Oct 2020

Neutrophils have more functions in the body than previously thought

Scientists at the Centro Nacional de Investigaciones Cardiovasculares have discovered that neutrophils, the most abundant cells of the innate immune system, have many more functions in the body than previously thought.

23 Oct 2020

Study: 90% of patients have detectable antibodies up to 7 months post contracting COVID-19

A new study led by Marc Veldhoen, principal investigator at Instituto de Medicina Molecular João Lobo Antunes (iMM; Portugal) with an interdisciplinary team of clinicians and researchers from Faculdade de Medicina da Universidade de Lisboa (FMUL) and Centro Hospitalar Lisboa Norte (CHLN) and collaborators at Instituto Português do Sangue e Transplantação (IPST), shows that 90% of subjects have detectable antibodies 40 days up to 7 months post contracting COVID-19.

23 Oct 2020

ACROBiosystems and the Fight Against COVID-19

In this interview, Dr. Yinang Jiang discusses ACROBiosystems and their efforts in the fight against COVID-19 and the search for a vaccine

From ACROBiosystems 23 Oct 2020

New method can detect high levels of COVID-19 antibodies

A more efficient and much faster method to assess high levels of neutralizing antibodies to COVID-19 could point the way to better understanding and treatment of the disease, according to new published findings by scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) and the University of Michigan (U-M).

23 Oct 2020

New research may shed light on challenges of developing universal flu vaccine

New research from an immunology team at the University of Chicago may shed light on the challenges of developing a universal flu vaccine that would provide long-lasting and broad protection against influenza viruses.

23 Oct 2020

Researchers develop a novel method to test for COVID-19 antibodies

When Dr. Stephen Smith of Seattle Children's Research Institute came down with muscle aches, gastrointestinal distress and a sudden loss of smell in late February, he suspected he had COVID-19.

23 Oct 2020